Scandion Oncology announces that the first patient has received treatment with SCO-101 in combination with FOLFIRI.

Scandion Oncology A/S (“Scandion Oncology”) is pleased to announce that the first patient has received treatment with SCO-101 and FOLFIRI with no unexpected SCO-101-related events observed. By measuring an exposure biomarker during treatment, it was observed that SCO-101 caused the expected changes in the level of this exposure biomarker, demonstrating that SCO-101 was present in the body in an effective concentration.

The release as fetched from its publisher. scandiononcology.com ↗